Related Experiment Video
Updated: May 8, 2025

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Combating TB Pathology: Advanced Diagnostics, Innovative Therapies, and Public Health Strategies: A Review
Satyajit Mohanty1, Manmeet Kaur Khanna2, Krishnendu Adhikary3
1Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi- 835215, Jharkhand, India.
This study reviews advancements in tuberculosis (TB) drug development, including new therapies and repurposed drugs. It highlights innovative strategies like immunotherapy and phytochemicals to accelerate TB treatment and combat resistance.
Area of Science:
- Microbiology
- Pharmacology
- Public Health
Background:
- Tuberculosis (TB) remains a significant global health issue caused by Mycobacterium tuberculosis.
- Effective TB management necessitates advanced diagnostics and novel therapeutic strategies.
- Drug resistance and treatment complexity pose major challenges to TB control.
Purpose of the Study:
- To explore current progress and challenges in anti-TB drug development, particularly those in clinical trials.
- To examine innovative therapeutic approaches, including immunotherapy, combination therapy, and phytochemical adjuncts.
- To assess strategies for accelerating TB treatment and enhancing patient adherence.
Main Methods:
- Review of scientific literature on anti-TB drug development and clinical trials.
- Analysis of emerging therapeutic modalities such as immunotherapy and drug repurposing.
- Examination of adjunct therapies including phytochemicals and public health interventions.
Main Results:
- Several novel anti-TB drugs are in various phases of clinical trials.
- Drug repurposing and combination therapies show promise in overcoming resistance.
- Immunotherapy and phytochemicals offer potential for enhanced treatment efficacy.
Conclusions:
- Innovative approaches are crucial for accelerating TB treatment and overcoming drug resistance.
- Integrated strategies combining novel drugs, adjunct therapies, and public health measures are vital.
- Further research and development are essential to improve global TB control outcomes.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Sputum Studies I: Gram Stain, cytology, and Acid-fast smear and culture
Gram Stain
The Gram Stain is an integral part of sputum studies. It involves the staining of sputum, which permits...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

